Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, discusses what’s coming for the treatment of genitourinary (GU) cancer in the next 12 months. Dr. Grivas predicts that the future will see more combinations and biomarkers, as currently this field does not use many biomarkers for patient selection. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).